Please login to the form below

Not currently logged in
Email:
Password:

LJPC-501

This page shows the latest LJPC-501 news and features for those working in and with pharma, biotech and healthcare.

La Jolla plans filing on back of blood pressure trial data

La Jolla plans filing on back of blood pressure trial data

The ATHOS-3 study found that LJPC-501, a synthetic formulation of natural peptide called angiotensin II that regulates blood pressure, hit its primary endpoint of raising blood pressure in patients ... All told, 70% of the LJPC-501-treated group in

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics